|
|
|
|
|
|
Sponsors and Collaborators: |
Imperial College London ALK-Abelló A/S |
Information provided by: | Imperial College London |
ClinicalTrials.gov Identifier: | NCT00135629 |
The purpose of this study is to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge. A once weekly cluster regimen of 2 injections per visit was employed during the up-dosing phase, followed by monthly maintenance injections of 100,000 SQ units. Symptom scores and need of rescue medication were recorded by patients during the study period. The size of early and late cutaneous response to allergen challenge was recorded and measured by a physician.
Condition | Intervention | Phase |
Rhinitis, Allergic, Seasonal |
Biological: Sublingual Alutard SQ grass pollen tablets (Phleum pratense) Procedure: Venepuncture: 100ml blood sample taken on 12 separate visits |
Phase III |
MedlinePlus related topics: | Hay Fever |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever: A Pilot Study. (Up-Dosing Study) |
Estimated Enrollment: | 18 |
Study Start Date: | October 2002 |
Estimated Study Completion Date: | February 2004 |
This was a single centre, randomised, double-blind placebo controlled trial of grass pollen injection immunotherapy (Alutard SQ, ALK Abello, Denmark) in adults with severe summer hayfever unresponsive to antihistamines and topical steroids. The main aim was to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge. A once weekly cluster regimen of 2 injections per visit was employed during the up-dosing phase, followed by monthly maintenance injections of 100,000 SQ units. Twelve patients received active treatment (mean age 31, 7 male) whilst 6 were given placebo (mean age 37, 2 male). The 24 hour skin response (size of swelling, (mm)) to intradermal allergen challenge (0.1, 1, 10 BU) was determined on alternate weeks during the 8 week up-dosing phase and then monthly up to 6 months and 3 monthly up to 11-13 months following initiation of treatment.
Results:
At the end of the up-dosing phase (approximately 8 weeks) there was a significant reduction in the size of the late phase response which was evident with all three intradermal doses (p=0.02 for 0.1 & 1 BU and p=0.04 for 10 BU). This reduction was sustained throughout the maintenance phase (p=0.04 for 0.1 BU and 0.01 for 1& 10BU).
Conclusion:
The up-dosing phase of grass pollen immunotherapy alone is sufficient to dampen the late skin response to allergen challenge. Whether or not this may be predictive of the clinical response to immunotherapy remains to be determined.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any of the following underlying conditions known or suspected to be present:
United Kingdom | |||||
Royal Brompton Hospital, NHLI Imperial College | |||||
London, United Kingdom, SW3 6LY |
Imperial College London |
ALK-Abelló A/S |
Principal Investigator: | Stephen R Durham, Professor | Royal Brompton Hospital, Imperial College, National Heart & Lung Institute |
Study ID Numbers: | DHRG-UpDosing |
First Received: | August 25, 2005 |
Last Updated: | August 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00135629 |
Health Authority: | United Kingdom: Research Ethics Committee |
|
|
|
|
|